# BofA RAISES Insmed stock price target on strong treprostinil data

BofA Securities raised its price target on Insmed (INSM) to $109 from $94, maintaining a Buy rating, after Insmed's treprostinil pro-drug (TPIP) topline results exceeded expectations, driving a 27% surge in the stock. The firm projects TPIP as a foundational treatment in PAH/PH-ILD, citing strong data showing a 35% reduction in pulmonary vascular resistance (PVR) and a 35.5-meter improvement in the six-minute walk distance (6MWD) test; other firms like Evercore ISI, Stifel, TD Cowen, and Jefferies have also raised their price targets, reflecting confidence in TPIP's potential.

Analysis

Insmed (NASDAQ:INSM) has garnered significant positive attention, evidenced by BofA Securities raising its price target to $109.00 from $94.00 while maintaining a Buy rating. This revision was prompted by exceptionally strong topline results for Insmed's treprostinil pro-drug, TPIP, which surpassed BofA's own bullish expectations. The market reacted vigorously, with INSM shares surging 27%, substantially outperforming the Nasdaq Biotechnology Index's 1% gain, and delivering a 23.4% return in the past week. The pivotal Phase 2 trial data for TPIP in pulmonary arterial hypertension (PAH) revealed a 35% reduction in pulmonary vascular resistance (PVR) and a 35.5-meter improvement in the six-minute walk distance (6MWD), exceeding both company and analyst forecasts. BofA Securities highlighted TPIP's potential to become a foundational treatment in PAH/PH-ILD, citing its strong efficacy, an apparently best-in-class profile, particularly concerning administration methods, and the expectation that efficacy could increase at higher doses while safety improves with longer titration. This optimism is broadly shared, with other firms including Evercore ISI (target $110), Stifel (target $110, noting TPIP could surpass brensocatib sales), TD Cowen (target $114), and Jefferies (target $121) also increasing their price targets; Truist Securities maintained a Buy rating with a $108 target. Insmed, now valued at $16.56 billion, has demonstrated robust revenue growth of 20.77% over the last twelve months. Future milestones for investors to watch include the planned initiation of a TPIP Phase 3 trial in early 2026 and the PDUFA date for brensocatib in 2025. While the outlook is predominantly positive, InvestingPro's analysis suggests INSM may not currently rank as a top undervalued stock.

Key Decisions for Investors

• Consider the highly positive TPIP clinical data and broad analyst upgrades as strong indicators of Insmed's growth potential in the PAH/PH-ILD market, potentially establishing TPIP as a cornerstone therapy.
• Monitor upcoming catalysts, notably the TPIP Phase 3 trial initiation in early 2026 and the brensocatib PDUFA date in 2025, for further validation of the company's pipeline and potential value inflection points.
• Acknowledge the significant recent stock appreciation, resulting in a $16.56 billion valuation; while TPIP's outlook is promising, investors should conduct thorough valuation analysis, especially considering InvestingPro's observation regarding its relative undervaluation compared to other opportunities.